Aspen Aerogels Inc. (ASPN) stock plummeted 27.91% in intraday trading on Wednesday, following the company's release of its fourth-quarter 2024 financial results and disappointing guidance for the first quarter of 2025.
While Aspen Aerogels reported better-than-expected Q4 revenue and earnings, beating analysts' estimates, the market reacted negatively to its weak Q1 2025 guidance. The company provided a Q1 revenue guidance range of $75 million to $95 million, significantly lower than the consensus estimate of $104.22 million. Additionally, its Q1 EPS guidance range of ($0.18) to $0.00 fell short of the consensus estimate of $0.08.
Adding to the stock's decline, Aspen Aerogels also announced that it is halting the construction of its Statesboro manufacturing facility, citing the need to focus resources on its existing operations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.